NeuroEM Therapeutics has appointed neurologist W. Scott Burgin, MD, as its first Chief Medical Officer. A longtime medical advisor to the company, Dr. Burgin joins its executive team as NeuroEM continues to study a noninvasive approach to brain health and neurological disease.
Dr. Burgin brings experience in clinical care, research, administration, and teaching, including work in stroke neurology, biomarkers, and AI. NeuroEM says he has authored more than 100 peer-reviewed articles and contributed to more than 75 clinical research projects. He will continue his academic work alongside his role at the company.
NeuroEM is developing a wearable technology that delivers radio-frequency electromagnetic energy through a head cap. Its research includes potential applications for Alzheimer’s disease. The company is also exploring a separate consumer wellness pathway through Wavium.
Moving a technology from research toward use in the real world requires careful clinical investigation, a clear understanding of its intended use, and attention to regulatory requirements. Dr. Burgin’s appointment adds medical leadership as the company continues that work.
The technology remains under development, and clinical evidence and regulatory review will determine its potential medical applications. We look forward to following NeuroEM’s research and the evidence it generates as the team advances its work.
Sources & further reading
For educational purposes. This material is not investment advice or an offer to invest.

